These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33798211)

  • 41. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
    Fisher M; Levy H; Fatelevich E; Afrimov Y; Ben-Shmuel A; Rosenfeld R; Noy-Porat T; Glinert I; Sittner A; Biber A; Belkin A; Bar-David E; Puni R; Levy I; Mazor O; Weiss S; Mechaly A
    Microbiol Spectr; 2021 Oct; 9(2):e0087021. PubMed ID: 34612689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
    Madhi SA; Kwatra G; Myers JE; Jassat W; Dhar N; Mukendi CK; Nana AJ; Blumberg L; Welch R; Ngorima-Mabhena N; Mutevedzi PC
    N Engl J Med; 2022 Apr; 386(14):1314-1326. PubMed ID: 35196424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland.
    Ulyte A; Radtke T; Abela IA; Haile SR; Blankenberger J; Jung R; Capelli C; Berger C; Frei A; Huber M; Schanz M; Schwarzmueller M; Trkola A; Fehr J; Puhan MA; Kriemler S
    BMJ Open; 2021 Jul; 11(7):e047483. PubMed ID: 34312201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.
    Wells PM; Doores KJ; Couvreur S; Nunez RM; Seow J; Graham C; Acors S; Kouphou N; Neil SJD; Tedder RS; Matos PM; Poulton K; Lista MJ; Dickenson RE; Sertkaya H; Maguire TJA; Scourfield EJ; Bowyer RCE; Hart D; O'Byrne A; Steel KJA; Hemmings O; Rosadas C; McClure MO; Capedevilla-Pujol J; Wolf J; Ourselin S; Brown MA; Malim MH; Spector T; Steves CJ
    J Infect; 2020 Dec; 81(6):931-936. PubMed ID: 33068628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?
    Haq M; Rehman A; Ahmad J; Zafar U; Ahmed S; Khan MA; Naveed A; Rajab H; Muhammad F; Naushad W; Aman M; Rehman HU; Ahmad S; Anwar S; Haq NU
    Infection; 2021 Oct; 49(5):983-988. PubMed ID: 34032997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.
    Bergeri I; Whelan MG; Ware H; Subissi L; Nardone A; Lewis HC; Li Z; Ma X; Valenciano M; Cheng B; Al Ariqi L; Rashidian A; Okeibunor J; Azim T; Wijesinghe P; Le LV; Vaughan A; Pebody R; Vicari A; Yan T; Yanes-Lane M; Cao C; Clifton DA; Cheng MP; Papenburg J; Buckeridge D; Bobrovitz N; Arora RK; Van Kerkhove MD;
    PLoS Med; 2022 Nov; 19(11):e1004107. PubMed ID: 36355774
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study.
    Mahajan S; Srinivasan R; Redlich CA; Huston SK; Anastasio KM; Cashman L; Massey DS; Dugan A; Witters D; Marlar J; Li SX; Lin Z; Hodge D; Chattopadhyay M; Adams MD; Lee C; Rao LV; Stewart C; Kuppusamy K; Ko AI; Krumholz HM
    Am J Med; 2021 Apr; 134(4):526-534.e11. PubMed ID: 33130124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis.
    Galanis P; Vraka I; Fragkou D; Bilali A; Kaitelidou D
    J Hosp Infect; 2021 Feb; 108():120-134. PubMed ID: 33212126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021.
    Lewis HC; Ware H; Whelan M; Subissi L; Li Z; Ma X; Nardone A; Valenciano M; Cheng B; Noel K; Cao C; Yanes-Lane M; Herring BL; Talisuna A; Ngoy N; Balde T; Clifton D; Van Kerkhove MD; Buckeridge D; Bobrovitz N; Okeibunor J; Arora RK; Bergeri I;
    BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35998978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020.
    Gidding HF; Machalek DA; Hendry AJ; Quinn HE; Vette K; Beard FH; Shilling HS; Hirani R; Gosbell IB; Irving DO; Hueston L; Downes M; Carlin JB; O'Sullivan MV; Dwyer DE; Kaldor JM; Macartney K
    Med J Aust; 2021 Mar; 214(4):179-185. PubMed ID: 33538019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis.
    Chisale MRO; Ramazanu S; Mwale SE; Kumwenda P; Chipeta M; Kaminga AC; Nkhata O; Nyambalo B; Chavura E; Mbakaya BC
    Rev Med Virol; 2022 Mar; 32(2):e2271. PubMed ID: 34228851
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.
    Gégout Petit A; Jeulin H; Legrand K; Jay N; Bochnakian A; Vallois P; Schvoerer E; Guillemin F
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms.
    Javed W; Abidi SHB; Baqar JB
    BMC Infect Dis; 2022 May; 22(1):481. PubMed ID: 35596145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Community-Based Seroprevalence of SARS-CoV-2 Antibodies following the First Wave of the COVID-19 Pandemic in Jazan Province, Saudi Arabia.
    Alhazmi A; Alamer E; Abdelwahab S; Khamjan N; Hamami A; Haddad M; Darraj M; Hashem AM; Algaissi A
    Int J Environ Res Public Health; 2021 Nov; 18(23):. PubMed ID: 34886175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review.
    Grant R; Dub T; Andrianou X; Nohynek H; Wilder-Smith A; Pezzotti P; Fontanet A
    BMJ Open; 2021 Apr; 11(4):e045425. PubMed ID: 33795310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021.
    Lyimo E; Fougeroux C; Malabeja A; Mbwana J; Hayuma PM; Liheluka E; Turner L; Gesase S; Lavstsen T; Lusingu JPA; Minja DTR; Wang CW
    BMC Infect Dis; 2022 Nov; 22(1):846. PubMed ID: 36371172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study.
    Hildebrandt A; Hökelekli O; Uflacker L; Rudolf H; Gatermann SG
    Int J Hyg Environ Health; 2021 Jun; 235():113771. PubMed ID: 34049092
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.
    Budziar W; Gembara K; Harhala M; Szymczak A; Jędruchniewicz N; Baniecki K; Pikies A; Nahorecki A; Hoffmann A; Kardaś A; Szewczyk-Dąbrowska A; Klimek T; Kaźmierczak Z; Witkiewicz W; Barczyk K; Dąbrowska K
    PLoS One; 2022; 17(2):e0253638. PubMed ID: 35113873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.